| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2022 | Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study | Kang Y.-K.; Morita S.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Chen L.-T.; Boku N. | Gastric Cancer | 4 | 5 | |
| 2020 | Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer | Satoh T.; Kang Y.-K.; Chao Y.; Ryu M.-H.; Kato K.; Cheol Chung H.; Chen J.-S.; Muro K.; Ki Kang W.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Tanimoto M.; Chen L.-T.; Boku N. | Gastric Cancer | 35 | 35 | |
| 2021 | Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma | CHIA-LANG HSU ; DA-LIANG OU ; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; ANN-LII CHENG ; YUNG-MING JENG ; CHIUN HSU | Liver Cancer | 27 | 30 | |
| 2021 | Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study | Chiu T.-J.; Su Y.-Y.; SHIH-HUNG YANG ; Li C.-P.; Bai L.-Y.; Chiang N.-J.; Chuang S.-C.; Shan Y.-S.; Chan D.-C.; Chen L.-T.; Yen C.-J.; Peng C.-M.; Chen Y.-Y.; Chen J.-S.; Chou W.-C. | Therapeutic Advances in Medical Oncology | 2 | 4 | |
| 2014 | A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer | Chao Y.; Hsieh J.-S.; Yeh H.-T.; Su Y.-C.; Wu C.-C.; Chen J.-S.; Tai C.-J.; Bai L.-Y.; KUN-HUEI YEH ; Su W.-C.; Li C.-P. | Cancer Chemotherapy and Pharmacology | 10 | 8 | |
| 2012 | Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer | WEN-HUNG KUO ; PO-HAN LIN ; Huang A.-C.; YIN-HSIU CHIEN ; Liu T.-P.; YEN-SHEN LU ; Bai L.-Y.; Sargeant A.M.; CHING-HUNG LIN ; ANN-LII CHENG ; Hsieh F.-J.; WUH-LIANG HWU ; KING-JEN CHANG | Journal of Human Genetics | 18 | 18 | |
| 2017 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. | The Lancet | 1400 | 1322 | |
| 2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab | Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. | Gastric Cancer | 34 | 30 | |
| 2013 | OSU-A9, an indole-3-carbinol derivative, induces cytotoxicity in acute myeloid leukemia through reactive oxygen species-mediated apoptosis | Bai L.-Y.; Weng J.-R.; Chiu C.-F.; Wu C.-Y.; Yeh S.-P.; Sargeant A.M.; PO-HAN LIN ; Liao Y.-M. | Biochemical Pharmacology | 27 | 27 | |
| 2014 | Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation | Yeh S.-P.; Lo W.-C.; Hsieh C.-Y.; Bai L.-Y.; Lin C.-C.; PO-HAN LIN ; Lin C.-Y.; Liao Y.-M.; Chiu C.-F. | Supportive Care in Cancer | 8 | 2 | |
| 2020 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. | Gastric Cancer | 113 | 107 | |
| 2013 | Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3 | PO-HAN LIN ; Lin C.-C.; Yang H.-I.; Li L.-Y.; Bai L.-Y.; Chiu C.-F.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-Y.; Ho C.-M.; Yang S.-F.; Peng C.-T.; Tsai F.-J.; Yeh S.-P. | Leukemia Research | 34 | 31 | |
| 2014 | Safety and efficacy of pegylated liposomal doxorubicinbased adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer | Lien M.-Y.; Liu L.-C.; Wang H.-C.; Yeh M.-H.; Chen C.-J.; Yeh S.-P.; Bai L.-Y.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-C.; Li L.-Y.; PO-HAN LIN ; Chiu C.-F. | Anticancer Research | 29 | 29 | |
| 2021 | Survival outcomes of management in metastatic gastric adenocarcinoma patients | Hu H.-M.; Tsai H.-J.; Ku H.-Y.; Lo S.-S.; Shan Y.-S.; Chang H.-C.; Chao Y.; Chen J.-S.; Chen S.-C.; CHUN-JU CHIANG ; Li A.F.-Y.; HSIU-PO WANG ; Wang T.-E.; Bai L.-Y.; MING-SHIANG WU ; Chen L.-T.; Liu T.-W.; Yang Y.-H. | Scientific Reports | 10 | 7 | |
| 2017 | A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice | PO-HAN LIN ; Li H.-Y.; Fan S.-C.; Yuan T.-H.; Chen M.; Hsu Y.-H.; Yang Y.-H.; Li L.-Y.; Yeh S.-P.; Bai L.-Y.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-C.; Lin C.-H.; Lien M.-Y.; Chen T.-T.; YEN-HSUAN NI ; Chiu C.-F. | Cancer Medicine | 44 | 39 | |
| 2013 | Young nasopharyngeal cancer patients with radiotherapy and chemotherapy are most prone to ischaemic risk of stroke: A national database, controlled cohort study | Chu C.-N.; PAU-CHUNG CHEN ; Bai L.-Y.; Muo C.-H.; Sung F.-C.; Chen S.-W. | Clinical Otolaryngology | 20 | 18 | |
